Lenalidomid Piramal

Lenalidomide, the active ingredient in Lenalidomid Piramal, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients, including those with relapsed or refractory disease, and is administered under specialist supervision.

GNH USA supplies Lenalidomid Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established quality‑assured distribution networks and regulatory compliance.

Lenalidomide is used in hematologic malignancies and bone marrow failure syndromes, targeting abnormal plasma cells and dysplastic hematopoiesis.

- Multiple myeloma: improves progression‑free survival, reduces tumor burden, and may extend overall survival in adult patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): decreases transfusion dependence, induces cytogenetic remission, and improves hematologic parameters in affected patients. - Relapsed/refractory multiple myeloma: used in combination with dexamethasone or other agents to achieve deeper responses and prolong disease control. - Multiple myeloma maintenance: administered after initial response to maintain remission.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia - Thrombocytopenia - Fatigue - Nausea

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia with infection risk - Secondary primary malignancies

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: regular CBC testing to detect neutropenia or thrombocytopenia. - Assess thrombotic risk: evaluate history of clotting disorders and consider prophylactic anticoagulation. - Contraindicated in pregnancy: avoid use and ensure effective contraception. - Adjust for renal impairment: dose may need modification in patients with reduced kidney function. - Avoid in patients with known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomid Piramal can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy. - Thalidomide or pomalidomide: additive teratogenic risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect. - Antiplatelet agents (aspirin, clopidogrel): increased bleeding risk. - Live vaccines: reduced immune response, consider timing.